NAT (nucleic acid testing) tests lead US IVD (in vitro diagnostic) growth
This article was originally published in Clinica
Comfortable - rather than exciting - growth of the US market for in vitro diagnostics is expected in the coming years. A new report from the Freedonia group (Cleveland, Ohio), In Vitro Diagnostics, predicts market expansion averaging some 7% in each of the next three years, revenues reaching $12,690 million in 2005. Growth will be led by demand for nucleic acid testing, as knowledge of the human genome begins to yield diagnostic tools.